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Abstract
Background: In systemic sclerosis (SSc), autoantibodies provide the most accurate tool to predict the disease subset
and pattern of organ involvement. Scleroderma autoantibodies target nucleic acids or DNA/RNA-binding proteins, thus
SSc immune complexes (ICs) can embed nucleic acids. Our working hypothesis envisaged that ICs containing
scleroderma-specific autoantibodies might elicit proinflammatory and profibrotic effects in skin fibroblasts.
Methods: Fibroblasts were isolated from skin biopsies obtained from healthy subjects and patients with diffuse
cutaneous SSc (dcSSc). ICs were purified by polyethylene-glycol precipitation from sera of SSc patients bearing different
autoantibodies. ICs from patients with systemic lupus erythematosus (SLE) and primary anti-phospholipid syndrome
(PAPS) and from normal healthy subjects (NHS) were used as controls. After incubation with ICs, fibroblasts were
evaluated for ICAM-1 expression, interleukin (IL)-6, IL-8, monocyte chemoattractant protein (MCP)-1, matrix
metalloproteinase (MMP)-2, tumor growth factor (TGF)-β1 and Pro-CollagenIα1 secretion, collagen (col)Iα1, mmp-1, toll-like
receptor (tlr)2, tlr3, tlr4, tlr7, tlr8, tlr9, interferon (ifn)-α, ifn-β and endothelin-1 mRNA, and NFκB, p38MAPK and SAPK-JNK
activation rate. Experiments were also performed after pretreatment with DNase I/RNase and NFκB/p38MAPK inhibitors.
Results: The antigenic reactivity for each SSc-IC mirrored the corresponding serum autoantibody specificity, while no
positivity was observed in NHS-ICs or sera. SSc-ICs but not NHS-ICs increased ICAM-1 expression, stimulated IL-6, IL-8,
MMP-2, MCP-1, TGF-β1 and Pro-CollagenIα1 secretion, upregulated et-1, ifn-α, ifn-β, tlr2, tlr3 and tlr4, and activated NFκB,
p38MAPK and SAPK-JNK. tlr9 was significantly upregulated by ARA-ICs, mmp-1 was significantly induced by ACA-ICs
whereas colIα1 was not modulated by any SSc-ICs. SLE-ICs and PAPS-ICs significantly upregulated MMP-2 and activated
NFκB, p38MAPK and SAPK-JNK. SLE-ICs and PAPS-ICs did not affect colIα1, mmp-1 and Pro-CollagenIα1. DNase I and
RNase treatment significantly reduced the upregulation of study mediators induced by SSc-ICs. Pretreatment with NFκB/
p38MAPK inhibitors suggested that response to anti-Th/To-ICs was preferentially mediated by p38MAPK whereas ATA-ICs,
ACA-ICs and ARA-ICs engaged both mediators. In dcSSc fibroblasts, stimulation with SSc-ICs and NHS-ICs upregulated IL-6
and IL-8.
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Conclusions: These data provide the first demonstration of the proinflammatory and profibrotic effects of SSc-ICs on
fibroblasts, suggesting the potential pathogenicity of SSc autoantibodies. These effects might be mediated by Toll-like
receptors via the interaction with nucleic acid fragments embedded in SSc-ICs.
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Background
Systemic sclerosis (SSc) is a chronic systemic auto-
immune disease characterized by three cardinal pro-
cesses: fibrotic derangement of the skin and visceral
organs, endothelial damage and immune activation [1].
A hallmark feature of SSc is the production of autoanti-
bodies: anti-nuclear antibodies (ANA) are detectable in
more than 95% of patients at diagnosis [2]. SSc-specific
autoantibodies typically precede disease onset, implicat-
ing they are not a mere reflection of the disease process
[3]. Importantly, they provide the most accurate tool to
predict disease subsets and the pattern of organ compli-
cations [4, 5]. Noteworthy, IgG transfer from SSc pa-
tients in skin-humanized SCID mice induced significant
dermal fibrosis [6]. Despite these in-vivo data, the pre-
cise diagnostic accuracy and the strong prognostic role
played by scleroderma-specific autoantibodies, scarce
in-vitro evidence has been raised in support of their
pathogenic potential. To date, available studies have
mainly focused on anti-DNA topoisomerase I antibodies
(ATA), that were demonstrated to bind to fibroblasts via
surface-bound topoisomerase I inducing adhesion and
activation of co-cultured monocytes [7, 8]. Antibodies
against centromeric proteins (ACA) were reported to
prevent the transactivation of the epidermal growth fac-
tor receptor and the subsequent secretion of interleukin
(IL)-8 [9].
Immune complexes (ICs) are formed upon interaction
between autoantibodies and soluble target antigens. ICs
contribute to the pathogenesis of several autoimmune
diseases, such as systemic lupus erythematosus (SLE),
Sjögren’s syndrome and rheumatoid arthritis [10–13].
Since the role of ICs in SSc has never been investigated,
the aim of this study was to assess the proinflammatory
and profibrotic effects of scleroderma ICs, using skin fi-
broblasts from healthy subjects as an in-vitro model.
Since scleroderma autoantibodies engage nucleic acids
or DNA/RNA-binding proteins as antigenic targets,
SSc-ICs can embed nucleic acids [14]. The effects of
SSc-ICs on target cells might thus be mediated by
Toll-like receptors (TLRs) interacting with nucleic acid
fragments. TLRs are expressed by many nonimmune
cells, including fibroblasts, and are crucial in sensing
pathogen-associated and damage-associated molecular
patterns. In humans, 10 TLRs have been described:
TLR2 and TLR4 are involved in the recognition of mi-
crobial molecules; TLR3 recognizes double-stranded
RNA; TLR7 and TLR8 bind single-stranded RNA; and
TLR9 engages single-stranded DNA [15].
As a whole, the data presented in this study provide the
first demonstration of the proinflammatory and profibro-
tic effects of SSc-ICs on healthy skin fibroblasts. The evi-
dence raised in this work suggests that such effects might
be ascribed to nucleic acid components of SSc-ICs via the
interaction with TLRs on target cells. As a whole, these
data shed new light on the pathogenic role of scleroder-
ma-associated autoantibodies, potentially broadening our
understanding of SSc etiopathogenesis.
Methods
Serum samples
Serum samples were obtained from 16 patients with SSc
fulfilling the 2013 ACR/EULAR criteria [16]. All patients
had ANA upon indirect immunofluorescence on HEp-2
cells, at a titer greater than 1:160, with staining patterns
consistent with the antigenic specificity. Five patients
carried ATA, five ACA, three anti-RNA polymerase III
antibodies (ARA) and three anti-Th/To antibodies
(anti-Th/To). The remaining autoantibody profile was
negative. In all cases, antibody reactivities against
scleroderma antigens were confirmed using two different
techniques: line blot (EUROLINE-SSc profile kit;
Euroimmun, Lubeck, Germany) and chemiluminescent
immunoassays (QUANTA Flash; INOVA Diagnostics,
San Diego, CA, USA). Seven patients were diagnosed
with diffuse cutaneous SSc (dcSSc), and the remaining
subjects had limited cutaneous involvement [17]. All pa-
tients were female, the median age was 48 years and the
median disease duration from the first non-Raynaud’s
phenomenon symptom to blood withdrawal was
31 months. Two SLE patients were recruited: one pa-
tient carried anti-Sm, anti-U1 ribonucleoprotein (RNP)
and anti-double stranded DNA antibodies; the other har-
bored anti-Sm [18]. Serum was also obtained from two
subjects with primary anti-phospholipid syndrome
(PAPS) and positive lupus anticoagulant test, anti-cardi-
olipin and anti-β2 glycoprotein I IgG antibodies [19].
Eight normal healthy subjects (NHS) with no auto-
immune disease and negative autoantibody profile were
enrolled. Serum samples were stored at − 20 °C.
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Healthy skin fibroblast cell culture
Dermal fibroblasts were isolated from skin biopsies from
eight NHS. Under local anesthesia with 1% xylocaine,
5-mm punch skin biopsies were performed in the distal
forearm. Samples were minced into small pieces, and
digested by collagenase type I (ThermoFisher Scientific
Inc., Waltham, MA, USA) for 2 h at 37 °C with 5% CO2.
After centrifugation at 300 × g for 10 min, pellets were re-
suspended in 1 ml D-MEM (Gibco-Life Technologies, Gro-
ningen, the Netherlands) supplemented with 20% fetal
bovine serum (FBS; PAA-GE Healthcare, Buckinghamshire,
UK), 2 mM glutamine (Sigma-Aldrich, Saint Louis, MO,
USA), penicillin (100 U/ml)–streptomycin (100 μg/ml)
(Sigma-Aldrich) and transferred into a T25 plate (Corning
Incorporated, NY, USA). Cultures were maintained at
37 °C in 5% CO2-humidified incubator until conflu-
ence. Nonadherent cells and dermal tissue were re-
moved by washing, and established fibroblasts were
passaged after trypsin/EDTA (ThermoFisher Scientific)
release up to the eight passage. Cells were maintained
in D-MEM with 10% FBS, 2 mM glutamine, penicillin
(100 U/ml)–streptomycin (100 μg/ml) (ThermoFisher
Scientific) or incubated overnight in D-MEM with 1%
FBS before functional studies.
The purity of fibroblast culture was 98% as detected
by flow cytometry using a mouse anti-human CD90 and
a mouse anti-human CD45 antibodies–PE conjugated
(BD Biosciences, San Jose, CA, USA).
Immune complexes
ICs were precipitated from sera of NHS and patients.
Briefly, serum samples were mixed with ice-cold 5%
polyethylene-glycol (PEG) 6000 (Sigma-Aldrich)–0.1 M
EDTA (Bioscience, Inc., La Jolla, CA, USA) and incu-
bated overnight at 4 °C. Samples were diluted three
times with 2.5% PEG 6000 in RPMI (Euroclone S.p.A.,
Pero, Italy), layered on top of 2.5% PEG 6000 supple-
mented with 5% human serum albumin (Sigma-Aldrich)
and centrifuged at 2100 × g at 4 °C for 20 min. Pellets
were dissolved in D-PBS to the initial serum volume and
immediately used at 1:2 dilution [20].
The IC amount in PEG precipitates was quantified
using Quanta Lite C1q CIC ELISA (INOVA Diagnos-
tics), a sensitive and specific assay exploiting soluble IC
binding to C1q [21, 22]. The presence of specific auto-
antibodies in PEG-precipitated ICs was tested using the
commercial EUROLINE-SSc profile kit. The nucleic acid
concentration (ng/μl) in IC preparations was evaluated
by NanoPhotometer Pearl at 260 nm (Implen GmbH,
München, Germany).
Every sample was used in triplicate, and each ex-
periment was repeated twice using SSc-ICs isolated
from all patients for each autoantibody specificity and
control ICs.
The potential endotoxin contamination of IC prepara-
tions was ruled out by limulus amoebocyte lysate (LAL)
gel-clot test (Pyrosate Kit, sensitivity 0.25 EU/ml; Associates
of Cape Cod Incorporated, East Falmouth, MA, USA).
ICAM-1 expression
ICAM-1 surface levels were evaluated by home-made
cell ELISA, as in previous studies on HUVECs [23].
Confluent fibroblast monolayers were rested in D-MEM
with 1% FBS overnight in a 96-well plate.
After 24-h incubation with 100 μl/well of SSc-ICs,
NHS-ICs, LPS (1 μg/ml; R&D Systems, Minneapolis, MN,
USA), poly(I:C) (1 μg/ml; Sigma-Aldrich) or medium alone,
cells were washed twice with HBSS (Sigma-Aldrich) and in-
cubated for 60 min at room temperature with 100 μl/well of
murine monoclonal IgG specific for human ICAM-1 (CD54;
R&D Systems). The antibody was used at a final dilution of
1:500 in HBSS-FBS 2.5%. After two additional washes, cells
were incubated for 90 min at room temperature with 100 μl
of phosphatase-conjugated goat anti-mouse IgG (Cappel,
Cochranville, PA, USA). The secondary antibody was used at
a dilution of 1:1000 in HBSS–FBS 10%. After two washes
with HBSS, 100 μl of the enzymatic substrate (p-nitrophenyl-
phosphate in 0.05 M Mg-carbonate buffer pH 9.8;
Sigma-Aldrich) was added. The optical density (OD) values
were evaluated at 405 nm after 30 min of incubation by a
semiautomatic reader (Titertek Multiskan MCC/340; Titer-
tek Instruments Inc., Pforzheim, Germany).
IL-6, IL-8, matrix metalloproteinase-2, monocyte
chemoattractant protein-1 and tumor growth factor
protein secretion
IL-6, IL-8, matrix metalloproteinase (MMP)-2, monocyte
chemoattractant protein (MCP)-1 and tumor growth
factor (TGF)-β1 release was evaluated in culture super-
natants after 48 h incubation with SSc-ICs, NHS-ICs or
TLR synthetic agonists (LPS and poly(I:C)) by commer-
cial ELISAs (R&D Systems).
Pro-CollagenIα1 secretion
Pro-CollagenIα1 secretion in culture supernatants was
evaluated after 24 h incubation with SSc-ICs, NHS-ICs
or recombinant human TGF-β1 (10 ng/ml; PreproTech,
Rocky Hill, JN, USA) by the human Pro-CollagenIα1
DuoSet ELISA Kit (R&D Systems).
tlr2, tlr3, tlr4, tlr7, tlr8, tlr9, interferon-α, interferon-β,
endothelin-1, collagenIα1 and mmp-1 mRNA expression
levels
Total RNA from fibroblasts was purified using Trizol
Reagent (ThermoFisher Scientific). Amplification Grade
DNase I (ThermoFisher Scientific) was used to eliminate re-
sidual genomic DNA. A reverse transcription reaction was
performed using the SuperScript™ First-Strand Synthesis
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System for RT-PCR (ThermoFisher Scientific). Universal
PCR Master Mix No AmpErase UNG (ThermoFisher
Scientific) was used for quantitative RT-PCR by the ABIPR-
ISM 7900 HT Sequence Detection System (ThermoFisher
Scientific). Quantification of mRNA expression was per-
formed with a TaqMan® Gene Expression Assay (Thermo-
Fisher Scientific) for each target gene (Table 1). RT-PCR was
performed after 24 h incubation with ICs. Expression levels
of the target genes (tlr2, tlr3, tlr4, tlr7, tlr8, tlr9, interferon
(ifn)-α, ifn-β, endothelin (et)-1, collagenIα1 (coIα1) and
mmp-1) were determined by the comparative Ct method
normalizing the target to the endogenous gene (gapdh).
Relative values of the target to the reference were expressed
as the fold change (RQ). The optimal time point to evaluate
the mRNA levels of colIα1 was set at 24 h based on a kinet-
ics curve of the mRNA response to stimulation with TGF-β.
Nuclear factor kappa B, p38 mitogen activated kinase and
SAPK-JNK activation rate
Fibroblast monolayers were incubated with SSc-ICs,
NHS-ICs, poly(I:C) and LPS. Total proteins were isolated
using RIPA Lysis Buffer added to Protease and Phosphatase
inhibitor cocktail (Sigma-Aldrich). Protein concentration was
evaluated using the BCA Protein Assay Kit (ThermoFisher
Scientific). Proteins were fractionated by NuPAGE BIS–TRIS
by 4–12% SDS-polyacrylamide precast gel electrophoresis
and transferred to nitrocellulose using iBlot Transfer Stacks
Nitrocellulose (ThermoFisher Scientific). Membranes were
blocked for 2 h at room temperature in PBS/0.05% Tween
20 (PT) (Bio-Rad Laboratories, Hercules, CA, USA) contain-
ing 5% nonfat milk powder (Mellin, Milan, Italy), and incu-
bated with anti-human nuclear factor kappa B (NFκB),
anti-human phosphorylated NFκB (pNFκB), anti-human p38
mitogen activated kinase (p38MAPK), anti-human phos-
phorylated p38MAPK (pp38MAPK), anti-human SAPK-JNK
or anti-human phosphorylated SAPK-JNK (anti-pSAPK-
JNK) antibodies (Cell Signaling Technology, Danvers, MA,
USA). After washing, membranes were incubated in PT/5%
nonfat milk powder plus HRP-conjugated secondary anti-
bodies (MP Biomedicals, Santa Ana, CA, USA) and devel-
oped using the ECL Plus Detection System (ThermoFisher
Scientific). Signals were detected using radiographic films
(Kodak, Rochester, NY, USA). ImageJ software (LI-COR Bio-
sciences, Lincoln, NE, USA) was used to analyze and quan-
tify gels.
SLE and APS immune complexes
The protein secretion of MMP-2 and Pro-CollagenIα1, the
mRNA levels of coIα1 and mmp-1, and the activation rate
of NFκB, p38MAPK, p54SAPK-JNK and p46SAPK-JNK
were also evaluated in response to stimulation with ICs
from SLE and PAPS sera.
DNase and RNase treatment
SSc-ICs were incubated for 1 h at 37 °C with recombin-
ant DNase I or RNase (20 KU/ml and 8 μg/ml, respect-
ively; Worthington Biochemical Corporation, Lakewood,
NJ, USA) and then added to cells for 24 h. RT-PCR for
tlr2, tlr3, ifn-α and et-1 was then performed.
NFκB and p38MAPK inhibitors
Cells were preincubated for 1 h at 37 °C with inhibitors of
NFκB (MG-132, 20 μmol; Sigma-Aldrich) and p38MAPK
(SB202190, 20 μmol; Cell Signaling Technology). The ex-
pression levels of IL-6 and the activation rates of NFκB
and p38MAPK were assessed by western blot analysis.
IL-8, TGF-β1 and Pro-CollagenIα1 were measured by
commercial ELISA kits in culture supernatants.
Scleroderma skin fibroblast cell culture
Dermal fibroblasts were isolated from two patients with
dcSSc and cultured following the same procedures de-
scribed for healthy fibroblasts. IL-6 and IL-8 secretion
levels were assessed in culture supernatants after 48 h
incubation with SSc-ICs, NHS-ICs or TLR synthetic ag-
onists (LPS and poly(I:C)) by commercial ELISAs (R&D
Systems).
Statistical analysis
Descriptive statistics were used to calculate the mean
and standard deviation (SD). Since our data were derived
from in-vitro experiments conducted under high con-
trolled conditions and originated from a high number of
cells, ANOVA was used to compare different experimen-
tal conditions, and post-hoc comparisons were assessed
by Dunnett’s test. With regards to nonhomogeneity of
variance assumption, Welch’s correction was applied
when required. Paired or unpaired t tests were per-
formed to compare mean values between two groups.
All analyses were performed with GraphPad Prism 5.01.
p < 0.05 was considered significant.
Table 1 TaqMan® Gene Expression Assays
Gene TaqMan® Gene Expression ID
tlr2 Hs01872448_s1
tlr3 Hs01551078_m1
tlr4 Hs00152939_m1
tlr7 Hs01933259_s1
tlr8 Hs00152972_m1
tlr9 Hs00370913_s1
ifn-α Hs00855471_g1
ifn-β Hs01077958_s1
et-1 Hs00174961_m1
colIα1 Hs00164004_m1
mmp-1 Hs00899658_m1
gapdh Hs99999905_m1
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The approval of the Institutional Review Board of Isti-
tuto G. Pini, Milan, Italy was obtained; all subjects pro-
vided written informed consent.
Results
Immune complex characterization
Quanta Lite C1q CIC ELISA confirmed that all PEG-
precipitated preparations contained ICs. SSc prepara-
tions exhibited significantly higher IC amounts com-
pared to NHS (50.77 ± 9.8 versus 5.95 ± 2.02, p < 0.01, t
= 4.477; cutoff 10.8 Eq/ml).
Using the EUROLINE-SSc profile kit on PEG-precipi-
tated preparations, reactivity against SSc-specific anti-
gens for each SSc-IC mirrored the corresponding serum
autoantibody specificity. No reactivity was observed in
NHS-ICs (Fig. 1).
To identify the optimal IC dilution in functional stud-
ies, a dose–response curve (1:2–1:64) was performed by
cell ELISA for ICAM-1 expression on the fibroblast sur-
face. A 1:2 dilution was selected as this allowed the high-
est response without affecting cell viability (Fig. 2).
Fig. 1 TaqMan® Gene Expression assays against SSc-specific antigens of PEG-precipitated ICs and corresponding sera evaluated by EUROLINE-SSc
profile kit. One ATA-IC and one NHS-IC presented as representative assay. CTR+, assay-positive control. a, Ro-52; b, PDGF receptor; c, Ku; d, PM-
Scl75; e, PM-Scl100; f, Th/To; g, NOR90; h, Fibrillarin; i, RP155; l, RP11; m, CENP B; n, CENP A; o, Scl-70 (DNA topoisomerase I). ATA anti-DNA
topoisomerase I antibodies, IC immune complex, NHS normal healthy subjects
Fig. 2 Dose–response dilution curve for ICAM-1 expression on
fibroblast cell surface. Fibroblasts exposed to serial two-fold dilutions
(from 1:2 to 1:64) of SSc-ICs and NHS-ICs, and ICAM-1 evaluated by
cell ELISA. anti-Th/To anti-Th/To antibodies, ATA anti-DNA
topoisomerase I antibodies, IC immune complex, NHS normal
healthy subjects, OD optical density
Fig. 3 ICAM-1 expression on fibroblasts stimulated with SSc-ICs
or NHS-ICs. Fibroblasts exposed to SSc-ICs or NHS-ICs (1:2
dilution). Poly(I:C) and LPS, at concentration of 1 μg/ml, used as
positive controls. ***p < 0.0001 versus medium. ACA anti-
centromeric protein antibodies, anti-Th/To anti-Th/To antibodies,
ARA anti-RNA polymerase III antibodies, ATA anti-DNA
topoisomerase I antibodies, IC immune complex, LPS
lipopolysaccharide, NHS normal healthy subjects, OD optical
density, poly(I:C) polyinosinic-polycytidylic acid
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ICAM-1 expression
SSc-ICs significantly induced ICAM-1 expression on fibro-
blast monolayers compared to medium. No increase in
ICAM-1 expression was observed with NHS-ICs. Poly(I:C)
and LPS elicited a significant increase in ICAM-1 protein
levels compared to medium (Fig. 3).
IL-6, IL-8, MMP-2 and MCP-1 secretion
All SSc-ICs, LPS and poly(I:C) upregulated IL-6 levels com-
pared to medium. Conversely, NHS-ICs did not have any
effect (Fig. 4a). All SSc-ICs, poly(I:C) and LPS elicited a sig-
nificant rise in IL-8 levels compared to medium (Fig. 4b).
Fibroblasts incubated with NHS-ICs exhibited IL-8 levels
similar to cells treated with medium alone. ATA-ICs,
ARA-ICs, anti-Th/To-ICs and LPS significantly upregu-
lated MMP-2 levels compared to medium. ACA-ICs,
poly(I:C) and NHS-ICs did not induce a significant increase
in MMP-2 protein levels (Fig. 4c).
All SSc-ICs, poly(I:C) and LPS significantly upregu-
lated MCP-1. NHS-ICs did not elicit a significant in-
crease in MCP-1 protein levels (Fig. 4d).
et-1 and ifn mRNA expression
LPS, ATA-ICs, ACA-ICs and anti-Th/To-ICs, but not
ARA-ICs, significantly upregulated et-1 levels compared
to the medium, while NHS-ICs and poly(I:C) did not
exert any effect (Fig. 5a).
ATA-ICs, ACA-ICs and anti-Th/To-ICs significantly
upregulated mRNA levels of ifn-α. Poly(I:C), LPS,
ARA-ICs and NHS-ICs did not significantly modulate
ifn-α mRNA (Fig. 5b). Poly(I:C), ATA-ICs, ACA-ICs and
anti-Th/To-ICs drove a significant increase of mRNA
levels of ifn-β. Stimulation with LPS, ARA-ICs and
NHS-ICs did not significantly affect mRNA of ifn-β
compared to culture medium (Fig. 5c).
TGF-β1 and Pro-CollagenIα1 secretion, and colIα1 and
mmp-1 mRNA expression
All SSc-ICs significantly increased TGF-β1 levels com-
pared to medium alone, while NHS-ICs did not exert
any effect (Fig. 6a). All SSc-ICs and TGF-β1 significantly
upregulated Pro-CollagenIα1 secretion in supernatants
compared to medium alone. NHS-ICs did not affect
protein levels (Fig. 6b). SSc-ICs and NHS-ICs did not
Fig. 4 IL-6, IL-8, MMP-2 and MCP-1 levels in culture supernatants from fibroblasts incubated with SSc-ICs or NHS-ICs. Fibroblasts exposed
to SSc-ICs or NHS-ICs (1:2 dilution). Poly(I:C) and LPS, at concentration of 1 μg/ml, used as positive controls. a IL-6; b IL-8; c MMP-2; d
MCP-1. **p < 0.001, ***p < 0.0001 versus medium. ACA anti-centromeric protein antibodies, anti-Th/To anti-Th/To antibodies, ARA anti-RNA
polymerase III antibodies, ATA anti-DNA topoisomerase I antibodies, IC immune complex, IL interleukin, LPS lipopolysaccharide, MCP
monocyte chemoattractant protein, MMP matrix metalloproteinase, NHS normal healthy subjects, poly(I:C) polyinosinic-polycytidylic acid
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modulate colIα1 mRNA expression. Conversely, TGF-β1
significantly increased colIα1 mRNA levels (Fig. 6c).
ACA-ICs drove a significant upregulation of mmp-1
while all the other SSc-ICs as well as NHS-ICs and
TGF-β1 did not significantly affect mmp-1 mRNA levels
(Fig. 6d).
tlr mRNA expression
All SSc-ICs, but not NHS-ICs, and both TLR agonists
drove a significant increase in tlr2 mRNA as compared
to medium (Fig. 7a). Similarly, all SSc-ICs, but not
NHS-ICs, induced a significant tlr3 upregulation; an in-
crease in tlr3 mRNA was observed with poly(I:C) and
LPS (Fig. 7b). LPS, ACA-ICs and ARA-ICs induced a
significant upregulation in tlr4 mRNA levels. Conversely,
ATA-ICs, anti-Th/To-ICs, NHS-ICs and poly(I:C) did
not affect tlr4 mRNA levels (Fig. 7c). tlr9 expression was
significantly modulated by ARA-ICs and poly(I:C). Dif-
ferently, ATA-ICs, ACA-ICs, anti-Th/To-ICs, NHS-ICs
and LPS did not affect tlr9 mRNA levels (Fig. 7d).
tlr7 and tlr8 mRNA could not be detected in fibroblasts.
Intracellular signaling pathways
ATA-ICs, ARA-ICs, anti-Th/To-ICs and LPS signifi-
cantly activated NFκB compared to the medium. Con-
versely, ACA-ICs and NHS-ICs did not elicit NFκB
phosphorylation (Fig. 8a). All SSc-ICs, but not
NHS-ICs, and LPS activated p38MAPK and p54SAPK-
JNK (Fig. 8b, c). ATA-ICs, ARA-ICs, anti-Th/To-ICs
and LPS induced a significant increased phosphoryl-
ation rate of p46SAPK-JNK. ACA-ICs and NHS-ICs did
not exert any effect on the phosphorylation rate of
p46SAPK-JNK (Fig. 8d).
Immune complexes from SLE and PAPS
SLE-ICs and PAPS-ICs phosphorylated NFκB (Fig. 9a),
p38MAPK (Fig. 9b), p54SAPK-JNK (Fig. 9c) and
p46SAPK-JNK (Fig. 9d). SLE-ICs and PAPS-ICs did not
induce a significant upregulation of the mRNA levels of
colIα1 (Fig. 10a) and mmp-1 (Fig. 10b) or of the
secretion of Pro-CollagenIα1 (Fig. 10c). SLE-ICs and
PAPS-ICs, as well as LPS, significantly upregulated
Fig. 5 et-1, ifn-α and ifn-β mRNA expression levels in fibroblasts stimulated with SSc-ICs or NHS-ICs. Fibroblasts exposed to SSc-ICs or NHS-ICs (1:2
dilution). Poly(I:C) and LPS, at concentration of 1 μg/ml, used as controls. a et-1; b ifn-α; c ifn-β. *p < 0.01, **p < 0.001, ***p < 0.0001 versus
medium. ACA anti-centromeric protein antibodies, anti-Th/To anti-Th/To antibodies, ARA anti-RNA polymerase III antibodies, ATA anti-DNA
topoisomerase I antibodies, et-1 endothelin-1, IFN interferon, IC immune complex, LPS lipopolysaccharide, NHS normal healthy subjects, poly(I:C)
polyinosinic-polycytidylic acid
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MMP-2 secretion compared to medium. NHS-ICs did
not significantly affect MMP-2 levels (Fig. 10d).
Nucleic acid content
SSc-ICs contained a higher amount of nucleic acids com-
pared to NHS-ICs (ssDNA 55.75 ± 16.41 ng/μl versus 43.11
± 12.36 ng/μl (p = 0.0470, t = 2.075); dsDNA 81.06 ±
29.84 ng/μl versus 49.13 ± 13.51 ng/μl (p = 0.0087, t =
2.867); RNA 62.70 ± 22.67 ng/μl versus 37.14 ±
10.42 ng/μl (p = 0.0086, t = 2.852)).
DNase I and RNase pretreatment modulated the ex-
pression of study mediators induced by SSc-ICs. Both
DNase I and RNase treatments prevented mRNA upreg-
ulation of et-1 by ATA-ICs and ACA-ICs (Fig. 11a), tlr2
by ACA-ICs and anti-Th/To-ICs (Fig. 11b), ifn-α by
ATA-ICs and anti-Th/To-ICs (Fig. 11c), and tlr3 by
ATA-ICs, ACA-ICs, ARA-ICs and anti-Th/To-ICs
(Fig. 11d). et-1 upregulation by anti-Th/To-ICs was
modulated by RNase only (Fig. 11a); tlr2 mRNA expres-
sion enhancement observed with ATA-ICs and ARA-ICs
was reduced by DNase I only (Fig. 11b). DNase I and
RNase treatments did not significantly affect study medi-
ators when cells were incubated with NHS-ICs.
NFκB and p38MAPK inhibitors
The efficacy of NFκB and p38MAPK inhibitors was con-
firmed by western blot analysis (Fig. 12a, b). When cells
were treated with NFκB inhibitor, the expression levels
of IL-6 in response to stimulation with LPS as well as all
SSc-ICs and NHS-ICs were not affected.
The inhibition of NFκB resulted in the significant
modulation of TGF-β1 in response to LPS, ATA-ICs,
ACA-ICs and ARA-ICs but not anti-Th/To-ICs and
NHS-ICs (Fig. 13a). Pretreatment with NFκB inhibitor
significantly downregulated the expression levels of
Pro-CollagenIα1 induced by TGF-β1 and ARA-ICs but
not ATA-ICs, ACA-ICs, anti-Th/To-ICs and NHS-ICs
(Fig. 13b). Pretreatment with NFκB inhibitor led to the
significant downregulation of the secretion levels of IL-8
induced by LPS, ATA-ICs and ACA-ICs but not
ARA-ICs, anti-Th/To-ICs and NHS-ICs (Fig. 13c).
The inhibition of p38MAPK led to the significant modula-
tion of TGF-β1 in response to LPS, ATA-ICs and anti-Th/
Fig. 6 TGF-β1 and Pro-CollagenIα1 secretion and colIα1 and mmp-1 mRNA expression in fibroblasts stimulated with SSc-ICs or NHS-ICs.
Fibroblasts exposed to SSc-ICs or NHS-ICs (1:2 dilution). TGF-β1 (10 ng/ml) used as positive control for collagen synthesis and secretion. a TGF-β1;
b Pro-CollagenIα1; c colIα1; d mmp-1. *p < 0.01, **p < 0.001, ***p < 0.0001 versus medium. ACA anti-centromeric protein antibodies, anti-Th/To
anti-Th/To antibodies, ARA anti-RNA polymerase III antibodies, ATA anti-DNA topoisomerase I antibodies, colIα1 collagenIα1, IC immune complex,
MMP matrix metalloproteinase, NHS normal healthy subjects, TGF tumor growth factor
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To-ICs but not ACA-ICs, ARA-ICs and NHS-ICs (Fig. 14a).
Pretreatment with p38MAPK inhibitor significantly down-
regulated the expression levels of Pro-CollagenIα1 induced
by TGF-β1 and anti-Th/To-ICs, but not ATA-ICs, ACA-ICs,
ARA-ICs and NHS-ICs (Fig. 14b). Pretreatment with
p38MAPK inhibitor resulted in the significant downregula-
tion of IL-8 induced by LPS and ACA-ICs but not ATA-ICs,
ARA-ICs, anti-Th/To-ICs and NHS-ICs (Fig. 14c). When
cells were pretreated with p38MAPK inhibitor, the expres-
sion of IL-6 induced by LPS, ATA-ICs, ACA-ICs, ARA-ICs
and anti-Th/To-ICs, but not NHS-ICs, was significantly af-
fected (Fig. 14d).
IL-6 and IL-8 secretion in scleroderma fibroblasts
In fibroblasts from subjects with dcSSc, all ICs—those
from SSc patients as well as NHS—upregulated both
IL-6 and IL-8 as compared to medium. Even poly(I:C)
and LPS elicited a significant raise in IL-6 and IL-8 levels
compared to medium (Fig. 15a, b, respectively).
Discussion
To our knowledge, this is the first study investigating in
vitro the pathogenic potential of ICs containing
SSc-specific antibodies. The first relevant observation
that emerged in this work consists of the confirmation
of IC content in all PEG-precipitated preparations, with
significantly higher IC amounts in the samples from
SSc patients compared to NHS. Consistently, early
works evaluating circulating ICs in serum samples from
SSc patients evinced a positivity rate similar to SLE
[24–27]. To note, the antigenic reactivity of each
PEG-precipitated preparation mirrored the autoanti-
body specificity of the original serum, thus confirming
that ICs contain scleroderma-specific autoantibodies.
Most importantly, functional experiments showed that
SSc-ICs can affect the functionality of skin fibroblasts,
the main effectors of tissue fibrosis. In particular, the
incubation with SSc-ICs modulated several molecules
involved in the three cardinal scleroderma pathophysio-
logic processes: vascular dysfunction (ET-1 and IL-8),
inflammation (ICAM-1, IL-6, IFNs and MCP-1) and fi-
brosis (TGF-β1 and Pro-CollagenIα1). Noteworthy,
SSc-ICs affected the protein but not the mRNA levels
of collagen, possibly due to the posttranscriptional
regulatory mechanism of collagen metabolism [28]; this
hypothesis should be confirmed in future experiments.
Fig. 7 tlr mRNA expression levels in fibroblasts stimulated with SSc-ICs or control NHS-ICs. Fibroblasts exposed to SSc-ICs or NHS-ICs (1:2 dilution).
Poly(I:C) and LPS, at concentration of 1 μg/ml, used as controls. a tlr2; b tlr3; c tlr4; d tlr9. **p < 0.001, ***p < 0.0001 versus medium. ACA anti-
centromeric protein antibodies, anti-Th/To anti-Th/To antibodies, ARA anti-RNA polymerase III antibodies, ATA anti-DNA topoisomerase I
antibodies, IC immune complex, LPS lipopolysaccharide, NHS normal healthy subjects, poly(I:C) polyinosinic-polycytidylic acid, TLR
Toll-like receptor
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Another aspect that still needs elucidation is the role of
type I IFNs. In our study, all SSc-ICs except ARA-ICs drove
an interferogenic response, consistent with previous obser-
vations, such as the high IFN levels in scleroderma sera and
skin samples and the IFN signature in peripheral blood cells
and tissue macrophages from SSc patients [29, 30]. In par-
ticular, ATA-ICs significantly increased both IFN-α and
IFN-β levels, in agreement with the already reported upreg-
ulation of IFNs elicited by ATA-positive sera in peripheral
blood mononuclear cells [31, 32]. If the earlier cited authors
proposed IFNs as early and prominent profibrotic media-
tors, it should be remembered that other investigators
claimed an antifibrotic effect for IFNs, warranting further
investigations [33, 34].
Our experiments suggest that SSc-ICs exert a specific
pathogenic role in scleroderma, as compared to disease
control ICs. Indeed, ICs from patients with autoimmune
conditions other than SSc were tested: PAPS and SLE
were identified as prototypical diseases. SLE is a systemic
autoimmune disease characterized by a flourishing auto-
antibody production and a polymorphic clinical presen-
tation [35]. APS is a systemic autoimmune condition
characterized by vascular thrombosis and/or obstetric
complications, in the persistent presence of circulating
anti-phospholipid antibodies [36]. In both diseases, auto-
antibodies have been shown to exert a pathogenic role
as well as a diagnostic one [37, 38]. Interestingly, in our
study, SLE-ICs and PAPS-ICs did not modulate molecules
Fig. 8 Intracellular signaling pathways in fibroblasts stimulated with SSc-ICs or NHS-ICs. Fibroblasts exposed to SSc-ICs or NHS-ICs (1:2 dilution).
LPS (1 μg/ml) used as control. a pNFκB/NFκB; b pp38MAPK/p38MAPK; c pp54SAPK-JNK/p54SAPK-JNK; d pp46SAPK-JNK/p46SAPK-JNK. Results
expressed as ratio of phosphorylated to nonphosphorylated forms, evaluated using ImageJ software. Western blot images representative of single
experiment. *p < 0.01, **p < 0.001, ***p < 0.0001 versus medium. ACA anti-centromeric protein antibodies, anti-Th/To anti-Th/To antibodies, ARA
anti-RNA polymerase III antibodies, ATA anti-DNA topoisomerase I antibodies, IC immune complex, LPS lipopolysaccharide, MAPK mitogen
activated kinase, NHS normal healthy subjects, NFκB nuclear factor kappa B, pNFκB phosphorylated NFκB, pp38MAPK phosphorylated p38MAPK,
pp54SAPK-JNK phosphorylated p54SAPK-JNK, pp46SAPK-JNK phosphorylated p46SAPK-JNK
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directly involved in fibrogenesis such as mmp-1, colIα1
and Pro-CollagenIα1. Both PAPS-ICs and SLE-ICs elicited
a significant activation of intracellular mediators which
are known to be involved in PAPS and SLE pathogenesis,
such as NFκB, p38MAPK and SAPK-JNK [37, 38].
According to our data, the pathogenic effects of
SSc-ICs on fibroblasts might be mediated by innate im-
munity sensors as TLRs. This hypothesis would allow
overcoming one of the strongest objections against the
pathogenicity of SSc autoantibodies, the intracellular
localization of target antigens. Indeed, while dendritic
and B cells could engage SSc autoantibodies via Fcγ re-
ceptor (FcγR), this is not the case of skin fibroblasts,
which lack FcγR [39]. To note, genetic, in-vitro, in-vivo
and ex-vivo findings are increasingly acknowledging
TLRs as master players in SSc pathogenesis [40]. Con-
sistently, SSc-ICs upregulated TLR expression, although
to a lower extent for tlr9. The recruitment of intracellu-
lar mediators downstream of TLRs was observed for
SSc-ICs but not NHS-ICs, further suggesting the poten-
tial involvement of TLRs in driving the SSc-IC signal.
We further investigated the contribution of intracellular
mediators by pretreating fibroblast cells with NFκB and
p38MAPK inhibitors. Data suggested that SSc-ICs might
engage intracellular signaling pathways differently: re-
sponse to anti-Th/To-ICs was preferentially mediated by
p38MAPK. Conversely, stimulation with ATA-ICs,
ACA-ICs and ARA-ICs appears to engage both intracel-
lular mediators.
It could thus be proposed that TLRs on target cells
might interact with SSc-ICs via the nucleic acid frag-
ments. TLR2, which does not recognize nucleic acids,
might recognize HMGB-1, which is incorporated in ICs
and acts as an agonist for both TLR2 and TLR4 [41, 42].
Fig. 9 Intracellular signaling pathways in fibroblasts stimulated with SLE-ICs, PAPS-ICs or NHS-ICs. Fibroblasts exposed to SLE-ICs, PAPS-ICs or NHS-
ICs (1:2 dilution). LPS (1 μg/ml) used as control. a pNFκB/NFκB; b pp38MAPK/p38MAPK; c pp54SAPK-JNK/p54SAPK-JNK; d pp46SAPK-JNK/
p46SAPK-JNK. Results expressed as ratio of phosphorylated to nonphosphorylated forms, evaluated using ImageJ software. Western blot images
representative of single experiment. *p < 0.01, **p < 0.001, ***p < 0.0001 versus medium. IC immune complex, LPS lipopolysaccharide, MAPK
mitogen activated kinase, NHS normal healthy subjects, NFκB nuclear factor kappa B, pNFκB phosphorylated NFκB, pp38MAPK phosphorylated
p38MAPK, pp54SAPK-JNK phosphorylated p54SAPK-JNK, pp46SAPK-JNK phosphorylated p46SAPK-JNK, PAPS primary anti-phospholipid syndrome,
SLE systemic lupus erythematosus
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Our working hypothesis is suggested by the significant
enrichment in nucleic acids of SSc-ICs compared to
NHS-ICs. As further support, DNase I and RNase pre-
treatment prevented the upregulation of mediators in-
duced by SSc-ICs, consistent with previous observations
[31]. These data fit well with the recent evidence of ele-
vated serum nucleosomes (histone proteins wrapped
with DNA fragments) among SSc patients [43]. Nucleic
acids embedded in ICs might be of endogenous nature:
DNA and RNA residues are released from damaged and
necrotic self-cells. Noteworthy, SSc patients exhibit in-
creased DNA damage in peripheral blood cells [44]; the
gene coding for DNASE1L3, an enzyme involved in
DNA fragmentation during apoptosis, is one of the
strongest susceptibility loci for SSc [45]. Nucleic acids
from pathogens might also be included in ICs; interest-
ingly, Epstein–Barr virus (EBV) was shown to infect
most fibroblasts and endothelial cells in the skin of SSc
patients [46].
Noteworthy, when fibroblasts from patients with
dcSSc were used as an in-vitro model, we observed a sig-
nificant difference in the modulation of IL-6 and IL-8 se-
cretion levels in response to stimulation with all SSc-ICs
as well as NHS-ICs. These findings are in agreement
with the well-known hyperresponsiveness of scleroderma
fibroblasts even to aspecific stimuli, prompting us to
focus our research on healthy skin fibroblasts in order to
reproduce the initiator phase of the disease.
As a whole, our findings allowed us to formulate a com-
prehensive hypothesis which postulates scleroderma-specific
autoantibodies embedded in SSc-ICs as novel players in
disease pathogenesis. The proposed pathogenic rele-
vance of SSc-ICs fits well with the evidence that
autoantibody positivity is the strongest predictor of
progression into full-blown SSc [5]. Further support for
the pathogenicity of autoantibodies comes from the
striking temporal clustering and casual link between
solid tumors and ARA-positive SSc [47, 48]. Indeed,
the POLR3A locus, coding for the antigenic target of
ARA, was altered in cancer tissue specimens from SSc
patients carrying ARA, leading to the synthesis of an
immunogenic enzyme resulting in T-cell-driven ARA
production and SSc onset [49].
We reckon that several functional autoantibodies
have already been described in SSc: anti-fibroblast anti-
bodies (AFA), anti-endothelial cell antibodies, anti-
bodies against platelet-derived growth factor receptor,
etc. However, differently from SSc-specific antibodies,
Fig. 10 colIα1 and mmp-1 mRNA expression and Pro-CollagenIα1 and MMP-2 secretion in fibroblasts stimulated with SLE-ICs, PAPS-ICs or NHS-
ICs. Fibroblasts exposed to PAPS-ICs, SLE-ICs or NHS-ICs (1:2 dilution). TGF-β1 (10 ng/ml) and LPS (1 μg/ml) used as positive control for collagen
synthesis and secretion. a colIα1; b mmp-1; c Pro-CollagenIα1; d MMP-2. *p < 0.01, **p < 0.001, ***p < 0.0001 versus medium. colIα1 collagenIα1, IC
immune complex, LPS lipopolysaccharide, MMP matrix metalloproteinase, NHS normal healthy subjects, PAPS primary anti-phospholipid
syndrome, SLE systemic lupus erythematosus, TGF tumor growth factor
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most of these functional autoantibodies can be detected
in a minority of patients’ sera and present a poor speci-
ficity for scleroderma, being positive in many other
autoimmune diseases and even in NHS [50]. In particu-
lar, AFA have been reported to upregulate ICAM-1,
IL-6, IL-1α, IL-1β, CCL2, CXCL8 and MMP-1, with
partial exploitation of TLR4, whereas collagen and tis-
sue inhibitor of MMP-1 were not affected [51, 52].
Interestingly, it has been suggested that anti-fibroblast
activity might be mediated by ATA: AFA purified from
Fig. 11 et-1, tlr2 and tlr3 expression levels in fibroblasts stimulated with SSc-ICs or NHS-ICs pretreated with DNase/RNase. SSc-ICs treated with
DNase I (20 KU/ml) or RNase (8 μg/ml) and then added to fibroblast cultures. a ATA-ICs, ACA-ICs and anti-Th/To-ICs on et-1; b ATA-ICs, ACA-ICs,
ARA-ICs and anti-Th/To-ICs on tlr2; c ATA-ICs and anti-Th/To-ICs on ifn-α; d ATA-ICs, ACA-ICs, ARA-ICs and anti-Th/To-ICs on tlr3. *p < 0.01, **p <
0.001, ***p < 0.0001 versus medium. ACA anti-centromeric protein antibodies, anti-Th/To anti-Th/To antibodies, ARA anti-RNA polymerase III
antibodies, ATA anti-DNA topoisomerase I antibodies, et-1 endothelin-1, IC immune complex, IFN interferon, TLR Toll-like receptor
Fig. 12 Confirmation of efficacy of NFκB and p38MAPK inhibitors by western blot analysis. Cells preincubated for 1 h at 37 °C with inhibitors of
NFκB and p38MAPK. Fibroblasts exposed to SSc-ICs or NHS-ICs (1:2 dilution). LPS (1 μg/ml) used as control. Results expressed as percentage of
inhibition of activated (a) NFκB and (b) p38MAPK (expressed as ratio of phosphorylated to nonphosphorylated forms). *p < 0.01, **p < 0.001 versus
medium. ACA anti-centromeric protein antibodies, anti-Th/To anti-Th/To antibodies, ARA anti-RNA polymerase III antibodies, ATA anti-DNA
topoisomerase I antibodies, IC immune complex, LPS lipopolysaccharide, NFκB nuclear factor kappa B, NHS normal healthy subjects, MAPK
mitogen activated kinase, pp38MAPK phosphorylated p38MAPK
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SSc patients strongly reacted with topoisomerase I and
AFA positivity at high titers correlated with pulmonary
involvement and death [7].
We acknowledge that our work presents intrinsic lim-
itations. Being an in-vitro study, it might be oversim-
plistic, not allowing adequate reproduction of the
complexity of scleroderma pathogenesis. It would be in-
triguing to test the effects of scleroderma ICs on endo-
thelial cells, macrophages and lymphocytes, some of
the mosaic of cells contributing to the many processes
that underpin fibrogenesis. In this regard, we have pre-
liminarily observed that endothelial cells stimulated
with SSc-ICs secrete a significantly higher amount of
TGF-β1, which might in turn act on fibroblasts, hence
promoting the acquisition of a profibrotic phenotype
(unpublished data). Indeed, further in-vitro experiments
using cell cocultures (e.g., endothelial cells and fibroblasts,
fibroblasts and macrophages, etc.) should be performed in
order to reproduce the multifaceted cellular orchestra im-
plicated in scleroderma etiopathogenesis. We reckon that
a major limitation of this study is the scarce number of
samples for each autoantibody specificity [53]. However,
the limited patient cohort does not impinge the robust-
ness of the conclusions of this study, whose aim was to
provide the first proof-of-concept of IC involvement in
the pathophysiology of SSc. In addition, some of the auto-
antibodies under investigation, such as ARA and anti-Th/
To, are quite uncommon in the Italian SSc population
[53], thus preventing the collection of a broader number
of samples. Nevertheless, we believe this study offers im-
portant insights into scleroderma pathophysiology: the ef-
fects of SSc-ICs should be appropriately confirmed using
samples from a wider cohort of SSc patients and the intra-
cellular mediators engaged by SSc-ICs should be further
characterized.
It would be tempting to postulate that the different
modulation of some study mediators that emerged upon
stimulation with the different scleroderma ICs might ac-
count for the characteristic clinical phenotype associated
with each autoantibody profile; however, the differential
response to SSc-ICs reacting with various antigens might
be ascribed to the IC contents of the preparations.
Fig. 13 TGF-β1, Pro-collagenIα1 and IL-8 in fibroblasts pretreated with NFκB inhibitor and incubated with SSc-ICs or NHS-ICs. Fibroblasts
pretreated with MG-132 (20 μmol), an NFκB inhibitor, and then exposed to SSc-ICs or NHS-ICs (1:2 dilution). LPS (1 μg/ml) and TGF-β1 (10 ng/ml)
used as positive controls. Results expressed as percentage of inhibition of a TGF-β1, b Pro-CollagenIα1 and c IL-8 in untreated versus MG-132-
treated cells. ***p < 0.0001 versus medium. ACA anti-centromeric protein antibodies, anti-Th/To anti-Th/To antibodies, ARA anti-RNA polymerase III
antibodies, ATA anti-DNA topoisomerase I antibodies, IC immune complex, IL interleukin, LPS lipopolysaccharide, NFκB nuclear factor kappa B,
NHS normal healthy subjects, TGF tumor growth factor
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Fig. 14 TGF-β1, Pro-collagenIα1, IL-8 and IL-6 in fibroblasts pretreated with p38MAPK inhibitor and incubated with SSc-ICs or NHS-ICs. Fibroblasts
pretreated with SB202190 (20 μmol), a p38MAPK inhibitor, and then exposed to SSc-ICs or NHS-ICs (1:2 dilution). LPS (1 μg/ml) and TGF-β1
(10 ng/ml) used as positive controls. Results expressed as percentage of inhibition of a TGF-β1, b Pro-CollagenIα1, c IL-8 and d IL-6 in untreated
versus SB202190-treated cells. *p < 0.01, **p < 0.001, ***p < 0.0001 versus medium. ACA anti-centromeric protein antibodies, anti-Th/To anti-Th/To
antibodies, ARA anti-RNA polymerase III antibodies, ATA anti-DNA topoisomerase I antibodies, IC immune complex, IL interleukin, LPS
lipopolysaccharide, NHS normal healthy subjects, MAPK p38 mitogen activated kinase, TGF tumor growth factor
Fig. 15 IL-6 and IL-8 in culture supernatants from dcSSc fibroblasts incubated with SSc-ICs or NHS-ICs. dcSSc fibroblasts exposed to SSc-ICs or
NHS-ICs (1:2 dilution). Poly(I:C) and LPS, at concentration of 1 μg/ml, used as positive controls. a IL-6; b IL-8. *p < 0.01, **p < 0.001, ***p < 0.0001
versus medium. ACA anti-centromeric protein antibodies, anti-Th/To anti-Th/To antibodies, ARA anti-RNA polymerase III antibodies, ATA anti-DNA
topoisomerase I antibodies, IC immune complex, IL interleukin, LPS lipopolysaccharide, NHS normal healthy subjects, poly(I:C)
polyinosinic-polycytidylic acid
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Unfortunately, normalization of the IC content of our
preparations could not be performed as PEG precipitates
should be used fresh.
As a whole, the data presented in this work might im-
pact our current understanding of SSc pathogenesis:
SSc-ICs could provide an additional player in the com-
plex interplay between autoimmunity, vascular damage
and excessive fibroblast activation culminating in tissue
fibrosis in the initiator phase of the disease. The rele-
vance of SSc-ICs might account for the strong diagnostic
and prognostic role scleroderma autoantibodies exert.
Autoantibody production might be favored by environ-
mental factors together with a predisposing genetic mi-
lieu, documented by the strong association with HLA
assets and polymorphisms in TLRs and downstream me-
diators. Hopefully, further characterizing the pathogenic
role of scleroderma autoantibodies could allow develop-
ing novel therapeutic strategies for a still barely treatable
disease.
Conclusion
This study shows that sera from scleroderma patients con-
tain ICs and proposes for the first time the potential
pathogenicity of SSc-ICs. Indeed, using skin fibroblasts
from NHS as an in-vitro model, we observed that SSc-ICs
can trigger proinflammatory and profibrotic mediators.
These effects might be mediated by TLRs via interaction
with nucleic acid fragments embedded in SSc-ICs. Our
data suggest that SSc-ICs might be a novel player in the
pathogenesis of scleroderma, fitting well with the diagnos-
tic and prognostic role of SSc-specific autoantibodies.
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